New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
07:41 EDTTSROTESARO price target lowered to $43 from $57 at RW Baird
Baird lowered its price target on TESARO citing the potential for a significant new competitor for one of its key drugs. The firm believes its Rolapitant P3 commercial thesis remains intact but worry the its competitor's formulation may be closer to reality than previously thought. Shares remain Outperform rated but cautious.
News For TSRO From The Last 14 Days
Check below for free stories on TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 10, 2014
09:20 EDTTSROTESARO management to meet with Leerink
Subscribe for More Information
September 8, 2014
12:22 EDTTSROOPKO reports licensee TESARO submits NDA for Rolapitant
Subscribe for More Information
08:10 EDTTSROTESARO submits rolapitant NDA to FDA
TESARO announced that it has submitted the New Drug Application, or NDA, for oral rolapitant to the FDA. Rolapitant is an investigational neurokinin-1 receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use